Compared with those in advanced-stage NSCLC, significantly more genomic mutations in EGFR and RBM10 (P = 0.038 and P = 0.019, respectively) and significantly fewer mutations in TP53 and CDKN2A (P < 0.0001 and P = 0.0001, respectively) were identified in early stage MPLC (Figure 3). This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.